A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. - Wikidata - wikimedia - TriplyDB

A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.

A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.

http://www.wikidata.org/entity/Q30445914

about

Antigen-specific active immunotherapy for ovarian cancer Antigen-specific active immunotherapy for ovarian cancer Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells.Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies.A mathematical framework for the selection of an optimal set of peptides for epitope-based vaccines.Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma Development of plant-produced protein body vaccine candidates for bluetongue virus.Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art ProtEx technology for the generation of novel therapeutic cancer vaccines Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.Immunotherapy for ovarian cancer: what's next?Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.Immunity and immune suppression in human ovarian cancer.Immunotherapeutic approaches to ovarian cancer treatment.Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment.Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.Immunotherapy in ovarian cancer.Opportunities in immunotherapy of ovarian cancer.A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients.Peptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma.Multipeptide vaccination in cancer patients.Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.Vaccine-based clinical trials in ovarian cancer.Cancer vaccines: should we be targeting patients with less aggressive disease?Next-generation peptide vaccines for advanced cancer.Dendritic cell immunotherapy in ovarian cancer.Towards in silico design of epitope-based vaccines.Therapeutic vaccines and cancer: focus on DPX-0907.The development and use of the E75 (HER2 369-377) peptide vaccine.A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.

P2860

Q24193567-0A9AC6A7-68A1-4E58-BF62-25919C4D6365 Q24240962-75429B6A-8581-48F0-8A89-518DCEE33148 Q26996829-54803A7B-431B-4600-B574-66A72A2010EA Q30409722-70C733E0-0CD1-493F-87D6-5D607EB773FA Q30425914-CDEBF484-DAD9-42E1-9262-DEDB9A143E74 Q30429708-29D03B05-24C6-49D8-9603-7168DF7E68A8 Q30434151-62A26F76-54B4-4506-B829-91F94ECE8E09 Q30436792-79C6AEBC-8015-434A-B4A7-7EB34521FDA2 Q33396199-DF28D281-3689-4A89-9341-A5E784B45A4D Q33731220-B3FD728C-A6DF-4383-A36E-817A00353F2B Q33743132-B0E611E1-5C85-4584-8D13-C6F42D85CD85 Q33907628-A8B38A1E-49B7-4D81-9826-53AC7E7F7EB8 Q34048819-82A949AD-0808-408E-8DA7-F68BD28B4471 Q34138324-3C49BE4B-C89D-4E03-BBF8-D57B5FB58833 Q34743514-8756AD8D-422F-4899-974B-CCCBFFF9DDC0 Q34993170-9D2B788B-E819-4EF3-8E13-205977314A9E Q35138135-F7034CC0-0141-4EEB-9AA7-B1A6962C8CB3 Q35213535-E13435D9-3487-4827-96BF-7062A273C0CA Q35214729-19753E23-7790-471F-A32C-AF945276F21D Q35820674-F1E9900E-31A7-4F23-AB64-05C16E8F4E36 Q36341084-2A575CA3-9A99-4132-BE32-C6D1C35421F0 Q36631249-7EFD6BD8-4BCA-471B-BA2C-059EEF01C2A3 Q36855245-E0268BCC-E642-42BA-85E9-A113AFE1F8F2 Q36958112-EAEE7A91-71D8-4649-8A1C-80F46FD43443 Q37146661-2280391E-5635-4FE3-8591-9C18B812ABE6 Q37148167-9D03C173-3E06-4C71-A256-061EB1D96C1C Q37224420-5F3F0266-B349-4A9F-A882-5A6FC917E136 Q37477273-E1B68042-F3CF-4D8A-988E-E641B8C4B70F Q37547268-D5586D3C-8CF5-4211-B0B1-34314ADB65A7 Q37716642-9FC8B30E-68CF-49C8-8287-8409915F091E Q37771268-184C2A35-D892-4011-8E32-87BEBA91E540 Q37873932-C409B808-ACBE-4035-8344-548B5E767B2E Q37892583-B7D15F08-D8BF-45BE-BBDC-854E18B2B2B2 Q38032880-A76EE201-C6A7-472F-9933-3274E08A41F1 Q38056246-16D70D98-CB65-4CD6-9328-65E0B770702F Q38069183-3BE4DC62-8FBE-425A-B55F-F9776A6B547D Q38088325-6889C91A-1CA2-4006-AF00-8900E0D362DA Q38193430-CC4D93D3-A6B9-41B8-9E81-3674DCB55BE2 Q38885965-DC53677C-7325-4CD4-B98F-9A0F99FC238D Q45073466-F9C29DE2-3021-45EB-93D1-B00B010CC01D

P2860

A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.

http://www.wikidata.org/entity/Q30445914

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

A multipeptide vaccine is safe ...... advanced stage ovarian cancer.

@ast

A multipeptide vaccine is safe ...... advanced stage ovarian cancer.

@en

type

label

A multipeptide vaccine is safe ...... advanced stage ovarian cancer.

@ast

A multipeptide vaccine is safe ...... advanced stage ovarian cancer.

@en

prefLabel

A multipeptide vaccine is safe ...... advanced stage ovarian cancer.

@ast

A multipeptide vaccine is safe ...... advanced stage ovarian cancer.

@en

P1433

Q30445914-1F8CDC1A-E9A6-4A81-BD4A-BE4A4B7EEB70

P1476

Q30445914-A4C068B7-765B-42CF-AA4F-635A7D8E7E37

P2093

Q30445914-061DBDDE-010A-420F-8EC8-C6639284A662

Q30445914-32B1A5D1-0633-47BF-983E-6AE4EDE90A39

Q30445914-3E53B9C3-A0D7-43E2-8B94-37D1C91F755D

Q30445914-4960ABBF-A181-4EC5-A279-8B04C92599C4

Q30445914-5272BD27-5C63-4CF6-BC73-35A3324DD977

Q30445914-7362BE30-1447-4B38-971B-8D5529D3165A

Q30445914-A19DB9E1-A925-4FAA-95E8-263069B2A6B3

Q30445914-B452D8D3-FF15-4B7B-904E-0DE7C678875C

Q30445914-C011FD3A-C305-4CEF-8F94-3736A67C7BD9

Q30445914-D2FECE51-7DAC-4AEF-9941-7AB4675C3C63

P304

Q30445914-7C2BC009-715D-47F0-B40A-33999377AA17

P31

Q30445914-A61362A8-22C6-40F9-B77C-60522522045F

P356

Q30445914-F0547562-43B1-4AE6-A170-516BC943948B

P433

Q30445914-92374456-C887-4B68-8ED2-21C56841A8ED

P478

Q30445914-0DA3659C-8314-4DE5-9C26-C40FA1E2833E

P50

Q30445914-31E271FB-2606-46D1-AFA7-935F0371D1FD

Q30445914-94373A54-48D9-4F06-BC82-ADAA448AB9CE

Q30445914-DCE4A757-030B-4609-B8F1-81FF5A1CA492

P577

Q30445914-58BDBD25-07E2-4D04-A001-F5C43F1BBFE7

P698

Q30445914-46A35FFA-4F84-4B4D-9E80-D81F5839856A

P921

Q30445914-41548864-F8F2-4A05-A807-2B1D63D19A50

P356

CJI.0B013E31816DAD10

P1433

Journal of Immunotherapy

P1476

A multipeptide vaccine is safe ...... advanced stage ovarian cancer.

@en

P2093

Arlene Yuan

http://www.w3.org/2001/XMLSchema#string

Carmel J Nail

http://www.w3.org/2001/XMLSchema#string

Cheryl Murphy

http://www.w3.org/2001/XMLSchema#string

Elizabeth Coleman

http://www.w3.org/2001/XMLSchema#string

Gina R Petroni

http://www.w3.org/2001/XMLSchema#string

Mark Smolkin

http://www.w3.org/2001/XMLSchema#string

Patrice Y Neese

http://www.w3.org/2001/XMLSchema#string

Scott A Boerner

http://www.w3.org/2001/XMLSchema#string

Walter C Olson

http://www.w3.org/2001/XMLSchema#string

William P Irvin

http://www.w3.org/2001/XMLSchema#string

P304

420-430

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/CJI.0B013E31816DAD10

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Craig Slingluff

Kimberly A Chianese-Bullock

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18391753

http://www.w3.org/2001/XMLSchema#string

P921